Table 2.
Lack of effect of CGP-39551 on the behavioral manifestations of CRH-induced seizures
| Treatment | N | Latency (min) | Duration (min) |
|---|---|---|---|
| CRH (150 × 10−12 mole) | 16 | 10.1± 2.0 | 140.3 ± 13.0 |
| CRH + CGP (30 mg/kg) | 9 | No seizuresa | No seizures |
| CRH + CGP (15 mg/kg) | 3 | 15, No seizures (2/3)b | 5, No seizures (2/3)b |
| CRH + CGP (10 mg/kg) | 3 | 6.6±2.8 | 14.0±1.60 |
| CRH + CGP (3 mg/kg) | 3 | 10.3±1.2 | 58.3±4.0 |
a
Abnormal behavior.
b
A single animal had seizures with a latency of 15 min. Two others did not have seizures.
Dose effect of administration of the competitive NMDA antagonist CGP-39551 (10 mg/kg) 40 min prior to infusion of CRH (150 × 10−12 mole) into the lateral cerebral ventricle of infant rats. Duration and latency to onset of limbic automatisms following infusion of CRH were monitored. All values are means ± S.E.M. CRH = corticotropin releasing hormone.